Emerging pathogens: Dynamics, mutation and drug resistance
- and others
This is the final report of a one-year, Laboratory Directed Research and Development (LDRD) project at Los Alamos National Laboratory (LANL). The objectives of this project were to develop models of the spread of pathogens, such as HIV-1 and influenza, in humans, and then to use the models to address the possibility of designing appropriate drug therapies that may limit the ability of the pathogen to escape treatment by mutating into a drug resistant form. We have developed a model of drug-resistance to amantidine and rimantadine, the two major antiviral drugs used to treat influenza, and have used the model to suggest treatment strategies during an epidemic.
- Research Organization:
- Los Alamos National Lab., NM (United States)
- Sponsoring Organization:
- USDOE Assistant Secretary for Human Resources and Administration, Washington, DC (United States)
- DOE Contract Number:
- W-7405-ENG-36
- OSTI ID:
- 534529
- Report Number(s):
- LA-UR--97-3505; ON: DE98000090
- Country of Publication:
- United States
- Language:
- English
Similar Records
Structures of HIV Protease Guide Inhibitor Design to Overcome Drug Resistance
Triple Combination Antiviral Drug (TCAD) Composed of Amantadine, Oseltamivir, and Ribavirin Impedes the Selection of Drug-Resistant Influenza A Virus
Solution NMR structure of the V27A drug resistant mutant of influenza A M2 channel
Book
·
Tue Jun 03 00:00:00 EDT 2008
·
OSTI ID:1008427
Triple Combination Antiviral Drug (TCAD) Composed of Amantadine, Oseltamivir, and Ribavirin Impedes the Selection of Drug-Resistant Influenza A Virus
Journal Article
·
Wed Dec 28 19:00:00 EST 2011
· PLoS ONE
·
OSTI ID:1627494
Solution NMR structure of the V27A drug resistant mutant of influenza A M2 channel
Journal Article
·
Fri Oct 08 00:00:00 EDT 2010
· Biochemical and Biophysical Research Communications
·
OSTI ID:22202801